Results 101 to 110 of about 10,710,575 (236)

Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones

open access: yes, 2018
Introduction The chemokines Stromal Cell-Derived Factor-1 alpha (SDF-1 alpha/CXCL12) and Monocyte Chemotactic Protein-1 (MCP-1/CCL2) have been implicated in breast cancer progression. We recently reported elevated systemic MCP-1 in breast cancer patients.
Dwyer, Róisín M.   +6 more
core   +1 more source

The Regulatory Mechanism and Value in Early Diagnosis and Prognosis Assessment of miR-4448 in Breast Cancer

open access: yesBreast Cancer: Targets and Therapy
Zhenyu Zhang,1,2,* Zhengrui Liu,1,2,* Chao Li,1 Fukai Wang,1 Zhaokun Tian,1 Xiaoyu Liu,1 Zhiyong Yu1 1Breast Surgery Ward Three, Shandong Cancer Hospital and Institute, Jinan, 250117, People’s Republic of China; 2Shandong First Medical ...
Zhang Z   +6 more
doaj  

ZNF689 loss impairs homologous recombination sensitizing triple-negative breast cancer to combined PARP and PD-L1 inhibition

open access: yesNature Communications
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by a poor prognosis due to the lack of effective targeted therapies.
Li-Ping Ge   +8 more
doaj   +1 more source

BCTB Non-Invasive Breast Cancer Samples and Images

open access: yes
This BCTB subcollection contains breast tissue and blood samples, and associated images, where a diagnosis of non-invasive cancer has been determined by a ...

core  

Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer

open access: yesSignal Transduction and Targeted Therapy
Neoadjuvant dual HER2 blockade with trastuzumab and pertuzumab plus chemotherapy represents the current standard-of-care for HER2-positive breast cancer.
Xiang-Rong Wu   +21 more
doaj   +1 more source

Current and future therapies for triple-negative breast cancer

open access: yesJournal of Hematology & Oncology
Triple-negative breast cancer remains an aggressive and biologically heterogeneous breast cancer subtype. Although the therapeutic landscape has expanded, durable disease control remains clinically challenging in many settings.
Zi-Xun Wang   +7 more
doaj   +1 more source

Prospective identification of tumorigenic breast cancer cells

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2003
M. Al-Hajj   +4 more
semanticscholar   +1 more source

Chinese expert consensus on standardized management of PI3K/AKT inhibitor-associated hyperglycemia in breast cancer (2026 edition)

open access: yesZhongguo aizheng zazhi
Breast cancer is the most common malignancy among women in China, with approximately 70% of cases being hormone receptor (HR)-positive. Although current therapeutic strategies have significantly improved patient outcomes, endocrine resistance remains a ...
Clinical Cancer Research Evaluation Committee of Chinese Medical Education Association   +2 more
doaj  

Home - About - Disclaimer - Privacy